FreeCME

Molecularly Targeted Therapies for Hematologic Malignancies

Jointly provided by The Leukemia & Lymphoma Society, RMEI, LLC, and Postgraduate Institute for Medicine.

Funding provided by The Leukemia & Lymphoma Society.

Release date: March 25, 2016

Valid through: March 25, 2017

Specialty: Hematology, Oncology

Target Audience:

This activity is primarily for researchers in hematology/oncology and for hematologists and oncologists who diagnose and treat patients with hematologic malignancies. The program is designed to provide the intended audience with cutting-edge research about newly approved and emerging molecularly targeted therapeutics in treating and improving outcomes of patients with hematologic malignancies.

This program consists of 5 continuing education activities.

Click the links below to review the activity launch pages containing full disclosure information.

Module 1 — Molecularly Targeted Therapy of Acute Myeloid Leukemia (AML) — 0.75 AMA PRA Category 1 Credits

Molecularly Targeted Therapy of Acute Myeloid Leukemia (AML) – Module 1 — A. Thomas Look, MD

Module 2 — Dissecting and Targeting Resistance in ALL: Signaling and metabolic dependencies in T-ALL — 0.75 AMA PRA Category 1 Credits

Module 2 — Adolfo Ferrando, MD, PhD

Module 3 — Advances in Biology and Treatments of Patients with Chronic Lymphocytic Leukemia: Targeting Survival/Growth Pathways — 0.75 AMA PRA Category 1 Credits

Module 3 — Thomas J. Kipps, MD, PhD

Module 4 — Aberrant Metabolism in Hematopoietic Malignancies and Its Therapeutic Implications — 0.75 AMA PRA Category 1 Credits

Module 4 — Pier Paolo Pandolfi, MD, PhD

Module 5 — Insights into the Pathophysiology and Therapeutic Targeting of Treatment Resistance in Myeloma and Panel Discussion and Q&A — 1.5 AMA PRA Category 1 Credits

Module 5 — Constantine S. Mitsiades, MD, PhD